Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess in vitro aggregation in patients with atrial...

Descripción completa

Detalles Bibliográficos
Autores principales: Sokol, Juraj, Nehaj, Frantisek, Ivankova, Jela, Mokan, Michal, Lisa, Lenka, Zolkova, Jana, Vadelova, Lubica, Mokan, Marian, Stasko, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573709/
https://www.ncbi.nlm.nih.gov/pubmed/33054412
http://dx.doi.org/10.1177/1076029620948585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573709/
https://www.ncbi.nlm.nih.gov/pubmed/33054412
http://dx.doi.org/10.1177/1076029620948585

Ejemplares similares